Monod Bio, a spinout company from the University of Washington’s Institute for Protein Design, has raised $25M to develop molecular biosensors designed to detect molecules linked to diseases.
The funding round, which was led by Matrix Capital, will be used to move to a new 12,000-square-foot space in South Lake Union and to double Monod Bio’s workforce.
“Monod is using synthetic biology to draw on the architecture of living organisms to attain high detection sensitivity and accuracy at scale, due to low costs with biosensors compared to conventional laboratory testing,” said Karan Takhar, managing partner at Matrix Capital.